Interleukin 2 News and Research

RSS

Superior T-cell immunity in COVID vaccinated

A recent study published in the journal Public Library of Science (PLOS) ONE presented the T cell and humoral immune responses following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection against the SARS-CoV-2 original and mutant strains.

27 Apr 2022

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Researchers assess the impact of interval administration of LD-IL-2 was examined in 18 T1D patients who received a three-day dosing interval.

10 Apr 2022

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

A recent study investigated the potency and functionality of T-cell and humoral responses against the SARS-CoV-2 wild-type strain and its variants.

28 Mar 2022

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

A recent study assessed the reactogenicity and immunogenicity induced by SARS-CoV-2 vaccines in adolescent individuals.

14 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Researchers develop an Omicron variant mRNA vaccine that is be more potent in generating nAbs as compared to other available vaccines.

6 Mar 2022

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

In a new study, researchers evaluated the immune responses induced by the mRNA-based SARS-CoV-2 vaccination against SARS-CoV-2 variants in multiple myeloma patients.

1 Mar 2022

Immune responses in patients with varying degrees of SARS-CoV-2 infection

In a recent research article published in the journal PLoS ONE, researchers looked at immunological responses in relation to established risk factors for serious illness. This prospective cohort study reports on long-lasting SARS-CoV-2 specific antibody and T-cellular immune responses six months after infection in rt-PCR confirmed cases of different illness severity (community and hospitalized patients).

24 Feb 2022

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

A team of scientists from the United States has recently demonstrated that current coronavirus disease 2019 (COVID-19) vaccines induce robust spike-specific T cell responses against the Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

1 Feb 2022

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

A new study assesses SARS-CoV-2 antigen-specific cytokine responses in a cohort of SARS-CoV-2 infected individuals with varying levels of disease.

26 Jan 2022

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

In a new study, researchers evaluated SARS-CoV-2 vaccination-induced T cell responses cross-recognition among the early and novel SARS-CoV-2 variants.

26 Jan 2022

A common cold may boost the immune system against COVID-19

A recent groundbreaking research paper published in the journal Nature Communications reveals the association of circulating SARS-CoV-2-specific T cells at exposure with lack of infection – implying the protective role for cross-reactive immune T cells in coronavirus disease 2019 (COVID-19) and opening the door for second-generation vaccines that could circumvent spike-antibody immune escape variants.

11 Jan 2022

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

The current study examines the role of heterologous vaccination, an area that lacks much clarity.

11 Jan 2022

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New data shows that, compared to adults, children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially activate pre-existing acquired immunity to prevalent common cold coronaviruses that cross-react with SARS-CoV-2 and protect them from severe disease.

24 Dec 2021

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

A group of researchers from various institutions developed a nucleoside-modified mRNA vaccine that encodes the SARS-CoV-2 N protein (mRNA-N) and is formulated in lipid nanoparticles for this investigation (LNP).

14 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

Interleukin 2 News and Research

Superior T-cell immunity in COVID vaccinated

Shared gene expression signatures in type 1 diabetics treated with IL-2 and COVID-19 patients

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Immunobridging study shows immunogenicity in adolescents receiving SARS-CoV-2 mRNA and inactivated vaccines

Combating COVID cytokine storm with targeted nucleic acid therapies

Omicron-specific mRNA vaccine generates immune responses in mice, hamsters and Macaques

Effect of mRNA-based COVID-19 vaccination in multiple myeloma patients

Immune responses in patients with varying degrees of SARS-CoV-2 infection

COVID-19 vaccines induce robust cellular immune response against SARS-CoV-2 Omicron

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Cross-recognition of SARS-CoV-2 vaccine-elicited T cell responses among different variants

A common cold may boost the immune system against COVID-19

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

Children with pre-existing immunity to common cold demonstrate better protection against COVID-19

New mRNA vaccine platform provides stronger protection against SARS-CoV-2 delta variant

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

Phase 2 study shows safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine

How durable is the immune response generated from the BNT162b2 vaccine?

The impact of multiple sclerosis therapy on COVID-19 vaccine efficacy

Flavonoids can potentially help prevent COVID-19-induced diarrhea, study finds

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News